Today: 10 June 2026
Browse Category

NYSE:UNF 19 December 2025 - 6 March 2026

UniFirst Corporation Stock Jumps After Report Says Cintas Is Nearing a Deal Above $275 a Share

UniFirst Corporation Stock Jumps After Report Says Cintas Is Nearing a Deal Above $275 a Share

Cintas is in advanced talks to acquire UniFirst for over $275 a share, or about $5.2 billion, Bloomberg Law reported. UniFirst stock jumped 13.6% in premarket trading Friday. The companies have negotiated on and off since 2022, with Cintas’ latest offer representing a 64% premium. Any deal would require a contract, shareholder approval, and could face antitrust scrutiny.
6 March 2026
··
UniFirst stock jumps after report of renewed Cintas takeover talks — what investors watch next

UniFirst stock jumps after report of renewed Cintas takeover talks — what investors watch next

UniFirst shares surged 15% to $230.01 premarket Tuesday after Bloomberg reported takeover talks with Cintas. Cintas confirmed a $275-per-share cash offer in December, valuing UniFirst at $5.2 billion. UniFirst’s board is reviewing the proposal with advisers and has not commented further. Trading volume in UniFirst quadrupled, while investors await updates from either company.
11 February 2026
··
UniFirst Corporation Stock (UNF) Jumps After Cintas Renews $275 Buyout Offer — News, Forecasts, and What’s Next

UniFirst Corporation Stock (UNF) Jumps After Cintas Renews $275 Buyout Offer — News, Forecasts, and What’s Next

Cintas Corporation made a $5.2 billion all-cash offer to acquire UniFirst at $275 per share, its third attempt to buy the company. UniFirst confirmed receipt of the non-binding proposal and said its board is reviewing the bid. UniFirst shares jumped 18% to $201 after the news, well below the offer price. Cintas included a $350 million reverse termination fee if regulators block the deal.
22 December 2025
···
UniFirst Corporation Stock (NYSE: UNF) Drops on Dec. 19, 2025 as Proxy Fight Aftershocks Collide With Mixed Wall Street Forecasts

UniFirst Corporation Stock (NYSE: UNF) Drops on Dec. 19, 2025 as Proxy Fight Aftershocks Collide With Mixed Wall Street Forecasts

UniFirst shares fell about 3% to $168.60 intraday on Dec. 19, 2025, after board election results showed company nominees Nowicki and Sintros won seats with support from Class B shares, despite activist nominees leading among common shareholders. Nowicki was named board chairman. Engine Capital, the activist investor, claimed a mandate for change based on the common stock vote.
19 December 2025
·

Stock Market Today

  • Northamber PLC Buys Back 200,000 Shares at 25p Each
    June 10, 2026, 9:06 AM EDT. Northamber PLC (AIM: NAR), a value-add Audio Visual and IT distributor, announced the purchase of 200,000 ordinary shares at 25 pence per share. These shares are to be issued to a consultant in exchange for services provided. Post-transaction, Northamber's total issued share capital will be 27,413,404 shares, with 27,113,404 carrying voting rights after accounting for 300,000 shares held in treasury. This transaction is disclosed under the UK's Market Abuse Regulation and relevant transparency rules. The shares were bought on the AIM market at 16:21:24. Investors can use the updated total share count to assess their shareholdings for regulatory notification requirements.

Latest articles

BlackBerry Drops Again; QNX Gains on the Line With June Earnings Ahead

BlackBerry Drops Again; QNX Gains on the Line With June Earnings Ahead

10 June 2026
BlackBerry shares dropped 4.84% to $8.84 Tuesday and slid further to $8.42 premarket Wednesday, erasing part of a 49% rally as investors question whether QNX and Secure Communications growth can justify recent gains ahead of Q1 fiscal 2027 earnings on June 25; the stock is now down 14.5% from last week’s close.
Nuvalent Trades Close to $124 After GSK’s $10.6 Billion Offer

Nuvalent Trades Close to $124 After GSK’s $10.6 Billion Offer

10 June 2026
Nuvalent soared 39.28% to $123.25 after GSK agreed to buy the company for $124 per share in cash, leaving a narrow 0.6% spread as investors shift focus to the $10.6 billion merger’s tender-offer timing, antitrust review, and FDA decision dates for two lung-cancer drugs in September and November 2026.
Go toTop